Cambridge, MA-based Bluebird Bio (NASDAQ: BLUE) has named Susanna High, formerly of Alnylam Pharmaceuticals and Millennium Pharmaceuticals, its chief operating officer. Andrew Obenshain, a veteran of Shire and Genzyme before that, will lead Bluebird’s operations in Europe.
From Our Editors · Podcast
Becoming the Cell & Gene Therapy Hub
Sponsored · Whitepaper
How a patient-centric, technology-driven approach can broaden access to research and reach patients regardless of geography, ethnicity, sex, or gender
PRA Health Sciences
Sponsored · Whitepaper
What the most successful life sciences fundraising pitch decks all have in common
Brex
